1. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44.
2. Pestalozzi B, Castiglione M, on behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (suppl. 2): ii7–10.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer V.2.2008. http://www.nccn. org/professionals/physician_gls/PDF/breast.pdf (accessed Nov 3, 2009).
4. Martin M, Pienkowski T, Mackey J et al., for the Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302–13.
5. Roché H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006; 24: 5664–71.
6. De Laurentiis M, Cancello G, D’Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44–53.
7. Miwa M, Ura M, Nishida M et al. Design of a novel oral fl uoropyrimidine carbamate, capecitabine, which generates 5-fl uorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274–81.
8. Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of effi cacy of capecitabine or 5’-deoxy-5-fl uorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999; 83: 127–34.
9. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5’-deoxy-5-fl uorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001; 7: 1079–86.
10. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine effi cacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013–9.
11. Toi M, Bando H, Horiguchi S et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004; 90: 2338–43.
12. O’Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812–23.
13. Lundin J, Lundin M, Holli K et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001; 19: 28–36.
14. Liu S, Chia SK, Mehl E et al. Progesterone receptor is a signifi cant factor associated with clinical outcomes and eff ect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2009; published online Feb 10. DOI:10.1007/s10549-009-0318-0.
15. Ravaioli A, Pasini G, Polselli A et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002; 72: 53–60.
16. Myers RE, Johnston M, Pritchard K et al., and the Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001; 164: 1439–44.
17. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191–9.
18. Muss HB, Berry DA, Cirrincione CT et al., for the CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055–65.
19. von Minckwitz G, Rezai M, Loibl S et al. Capecitabine given concomitantly or in sequence with EC→docetaxel as neoadjuvant treatment for early breast cancer: GeparQuattro—a GBG/AGO intergroup-study. Eur J Cancer Suppl 2008; 7: 108 (abstr 203).
20. Steger GG, Greil R, Jakesz R et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer: fi rst results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24). Eur J Cancer Suppl 2009; 7: 3 (abstr 4BA).
21. Berton-Rigaud D, Roché H, Penault-Llorca F et al. Benefi t of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T). 2008 ASCO Annual Meeting; May 30–June 3, 2008; Chicago, IL, USA. Abstract 598.
22. Kosmas C, Kallistratos MS, Kopterides P et al. Cardiotoxicity of fl uoropyrimidines in diff erent schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75–82.
23. Swain SM, Jeong J-H, Geyer CE et al. NSABP B-30: defi nitive analysis of patient outcome from a randomized trial evaluating diff erent schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. 31st Annual San Antonio Breast Cancer Symposium; Dec 10–14, 2008; San Antonio, TX, USA. Abstract 75.
24. Eiermann W, Pienkowski T, Crown J et al. BCIRG 005 main effi cacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer. 31st Annual San Antonio Breast Cancer Symposium; Dec 10–14, 2008; San Antonio, TX, USA. Abstract 77.
25. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al, for the FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20.
26. Harvey V, Mouridsen H, Semiglazov V et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24: 4963–70.
27. Bono P, Kellokumpu-Lehtinen P-L, Alanko T et al. Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial. Ann Oncol 2009, 20: 595–96.
28. Leonard R, O’Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17: 1379–85.
29. Gluck S, Russell C, O’Shaughnessy J et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. 2009 ASCO Annual Meeting; May 29–June 2, 2009; Orlando, FL, USA. Abstract 1024.
30. Ellis P, Barrett-Lee P, Johnson L et al. For the TACT Trial Management Group and the TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009; 373: 1681–92.

И.В.Колядина, И.В.Поддубная

Кафедра онкологии РМАПО, Москва